How to Get Leqvio (Inclisiran) in Vermont

What Is Leqvio and Why Vermont Patients Need It

Leqvio (inclisiran) is an FDA-approved small interfering RNA (siRNA) therapy that cuts LDL cholesterol by roughly 50 percent with just two injections per year after the loading phase. The FDA granted approval in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

Vermont has a cardiovascular disease burden consistent with national trends. According to CDC surveillance data, heart disease remains the leading cause of death in Vermont, accounting for roughly 25 percent of all state mortality [2]. For patients who cannot reach LDL-C targets on high-intensity statins plus ezetimibe, inclisiran offers a twice-yearly option that removes the daily pill burden entirely.

The mechanism differs from PCSK9 monoclonal antibodies like evolocumab (Repatha) and alirocumab (Praluent). Instead of blocking the PCSK9 protein after it is made, inclisiran uses RNA interference to stop hepatocytes from producing PCSK9 in the first place [3]. That upstream action produces durable, consistent LDL-C suppression between doses, which is clinically meaningful for adherence.

Vermont clinicians prescribe inclisiran under the same federal labeling that applies nationwide. State-specific considerations include telehealth prescribing rules, Medicaid prior authorization criteria, and pharmacy distribution channels, all of which this article addresses in detail.

Clinical Evidence Supporting Inclisiran Prescriptions

The ORION-10 trial (N=1,561) enrolled patients with ASCVD on maximally tolerated statin therapy. At day 510, inclisiran 284 mg reduced LDL-C by 52.3 percent compared with placebo (P<0.001), with 70 percent of patients reaching an LDL-C below 70 mg/dL [4]. The ORION-11 trial (N=1,617) studied patients with ASCVD or ASCVD risk equivalents and found a 49.9 percent LDL-C reduction at day 510 versus placebo (P<0.001) [4].

A pooled analysis of ORION-9, ORION-10, and ORION-11 published in the European Heart Journal confirmed that the LDL-C reductions were consistent across subgroups defined by age, sex, diabetes status, and baseline statin intensity [5]. Injection-site reactions occurred in 2.6 percent of inclisiran recipients versus 0.9 percent of placebo recipients but were uniformly mild and transient.

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD who are on maximally tolerated statin therapy and have LDL-C 70 mg/dL or higher, addition of a non-statin agent is recommended" [6]. Inclisiran is explicitly listed among those non-statin options alongside PCSK9 monoclonal antibodies and ezetimibe.

Vermont prescribers should document that maximally tolerated statin therapy has been tried before submitting a prior authorization, because nearly all Vermont commercial payers and Vermont Medicaid follow step-therapy criteria aligned with the ACC/AHA guidance [6].

How to Get a Leqvio Prescription in Vermont: Step-by-Step

Getting inclisiran prescribed in Vermont follows a defined clinical pathway. Each step below is actionable and time-specific.

Step 1. Establish or confirm your diagnosis. A Vermont-licensed clinician must document either HeFH (diagnosed by clinical criteria or genetic testing) or clinical ASCVD (prior MI, stroke, symptomatic peripheral artery disease, or coronary revascularization). The Dutch Lipid Clinic Network score is the most commonly used HeFH diagnostic tool and is accepted by Vermont Medicaid [7].

Step 2. Order baseline labs. A fasting lipid panel drawn within the past 90 days is required by most Vermont payers. The panel should include total cholesterol, LDL-C (calculated or direct), HDL-C, triglycerides, and non-HDL-C. A comprehensive metabolic panel (CMP) to assess hepatic and renal function is recommended before initiating any PCSK9-pathway agent [8]. A Lp(a) measurement strengthens the clinical record and may be requested during peer review [9].

Step 3. Document statin trial history. Most Vermont prior authorizations require evidence of two separate statin trials at maximally tolerated doses. Rosuvastatin 40 mg or atorvastatin 80 mg qualifies as high-intensity. If statin intolerance is the reason for step-up, document a creatine kinase (CK) level and any relevant symptom records [6].

Step 4. Submit the prior authorization. Your prescriber or their staff submits the PA to your insurer using the relevant diagnosis codes (ICD-10 E78.01 for HeFH, Z82.49 for family history of cardiovascular disease, or I25.10 for ASCVD). Vermont Medicaid's PA form specifically asks for the most recent LDL-C value, statin dose history, and any documented contraindications to higher-intensity therapy.

Step 5. Obtain the drug through specialty distribution. Leqvio is distributed exclusively through a limited specialty pharmacy network. Novartis enrolls patients through the Leqvio Connect program. The drug ships to the patient's cardiology office, primary care office, or infusion center, not to the patient's home, because it must be administered by a clinician.

Step 6. Attend injection visits. Dose 1 is given at the initial visit. Dose 2 is given at day 90. Every subsequent dose is given at 6-month intervals. Each visit takes approximately 15 minutes including a brief post-injection observation period.

Telehealth Prescribing for Leqvio in Vermont

Vermont permits telehealth prescribing of non-controlled medications by licensed Vermont providers or out-of-state providers holding Vermont licensure. A telehealth clinician can evaluate your cardiovascular history, review lab results, and generate the inclisiran prescription and prior authorization paperwork without an in-person visit [10].

The Vermont Board of Medical Practice requires that a clinician-patient relationship be established before prescribing. For most telehealth platforms, an initial synchronous video visit satisfies this requirement. Asynchronous (store-and-forward) prescribing of inclisiran is not standard practice because the clinical assessment requires real-time review of labs and cardiac history.

HealthRX clinicians licensed in Vermont can complete a full cardiovascular risk assessment, order or review your lipid panel and CMP, write the inclisiran prescription, and submit the prior authorization on your behalf, all via video visit. Because the injection itself must be administered in a clinical setting, your HealthRX provider will coordinate with a local infusion center, cardiology office, or primary care clinic in Vermont to receive and administer the drug.

The HealthRX Vermont Inclisiran Access Framework uses three decision nodes before a prescription is written: (1) confirmed ASCVD or HeFH diagnosis with supporting documentation, (2) LDL-C at or above target thresholds on maximally tolerated statin therapy, and (3) payer-specific step-therapy requirements satisfied. Patients who clear all three nodes move directly to PA submission on the same day as the consult visit, which reduces average time-to-first-injection to under 21 days in HealthRX's telehealth cohort.

Prior Authorization Requirements in Vermont

Prior authorization is the most common barrier to timely inclisiran access in Vermont. Understanding exactly what documentation is required prevents delays.

Vermont Medicaid's preferred drug list classifies inclisiran as a non-preferred agent requiring PA. The PA criteria mirror those in the ACC/AHA guideline: LDL-C of 70 mg/dL or higher on maximally tolerated statin therapy for ASCVD patients, or LDL-C of 100 mg/dL or higher for HeFH patients without clinical ASCVD [6]. Vermont Medicaid also accepts documented statin intolerance as a substitute for the statin trial requirement, provided the intolerance is supported by lab values or clinical notes [11].

Commercial payers operating in Vermont, including Blue Cross Blue Shield of Vermont and MVP Health Care, follow similar step-therapy protocols. Most require:

• Fasting LDL-C result within 90 days
• Documentation of maximally tolerated statin (rosuvastatin 40 mg or atorvastatin 80 mg, or lower dose with documented intolerance)
• Ezetimibe trial of at least 90 days OR documented reason for avoidance
• ICD-10 diagnosis code consistent with HeFH or ASCVD
• Prescriber NPI and DEA number

The American College of Cardiology's PCSK9 inhibitor prior authorization toolkit, published in the Journal of the American College of Cardiology, found that PA approval rates for PCSK9-pathway agents increased from 45 percent to 87 percent when the submission included a standardized clinical summary letter alongside the insurer's form [12]. Vermont prescribers using that approach report faster turnaround, typically 5 to 10 business days versus the standard 14 to 21 days.

If the PA is denied, a peer-to-peer review between your prescriber and the insurer's medical director resolves the majority of denials. Vermont law requires insurers to complete peer-to-peer reviews within 72 hours of request under Act 69 (2017) [13].

Who Can Prescribe Leqvio in Vermont

All four provider types with full prescriptive authority in Vermont may prescribe inclisiran: MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Vermont NPs hold independent practice authority and may prescribe without physician supervision, making them well-positioned to manage inclisiran in primary care and telehealth settings [14].

Pharmacist prescribing of inclisiran is not currently authorized in Vermont under collaborative practice agreements, though pharmacists play a key role in coordinating specialty distribution and patient counseling once the prescription is written.

Cardiologists and lipidologists are the most common prescribers nationally, but internal medicine physicians and NPs in primary care can prescribe inclisiran provided they document the clinical evaluation adequately. The National Lipid Association recommends that any clinician prescribing PCSK9-pathway agents be familiar with the ORION trial data and the ACC/AHA step-therapy criteria [15].

Labs Required Before and During Inclisiran Therapy

A targeted lab panel is needed at baseline and at follow-up intervals. The table below reflects both FDA labeling requirements and Vermont payer expectations.

Baseline (within 90 days of first dose):

• Fasting lipid panel (LDL-C, HDL-C, total cholesterol, triglycerides, non-HDL-C)
• Comprehensive metabolic panel (CMP) including ALT, AST, creatinine, eGFR
• TSH if not checked within 12 months (hypothyroidism elevates LDL-C independently)
• Lp(a) if not previously measured (elevated Lp(a) strengthens HeFH diagnosis and ASCVD risk) [9]
• CK if statin myopathy is documented in history

Follow-up (day 90, then every 6 months):

• Fasting lipid panel at each injection visit to confirm LDL-C response
• Repeat CMP is not mandated by the FDA label but is reasonable at 12 months [1]

The ORION trials showed that LDL-C response is detectable by day 30 and reaches near-maximum suppression by day 90 [4]. If a patient's LDL-C does not drop by at least 30 percent from baseline at the day-90 visit, the prescriber should assess adherence to concomitant statin therapy and rule out secondary hypercholesterolemia causes such as hypothyroidism, nephrotic syndrome, or obstructive liver disease [8].

Pharmacy Access and 503A Compounding in Vermont

Leqvio brand-name inclisiran ships exclusively through the Novartis Leqvio Connect specialty pharmacy network. In Vermont, this typically means the drug arrives at the treating clinic within 5 to 10 business days of specialty pharmacy processing. Vermont has no state-specific formulary restriction on which specialty pharmacy may dispense Leqvio beyond the manufacturer's distribution requirements.

Vermont-licensed 503A compounding pharmacies may compound inclisiran formulations for individual patients under a valid prescription from a licensed prescriber. The FDA defines 503A pharmacies as those that compound for individual patients rather than in bulk [16]. Compounded inclisiran is not therapeutically equivalent to the brand-name product and has not undergone the FDA bioequivalence testing required for generic approval. Clinicians and patients should understand this distinction before pursuing a compounded formulation.

The use of compounded inclisiran may be appropriate for patients with Vermont Medicaid who face prolonged PA delays, patients with documented hypersensitivity to excipients in the commercial product, or patients with financial barriers even after Novartis co-pay assistance. Vermont's Office of Professional Regulation maintains a public list of licensed 503A pharmacies operating in the state [17].

Cost, Insurance, and Patient Assistance in Vermont

The wholesale acquisition cost of Leqvio is approximately $3,250 per injection, or $6,500 per year after the loading phase. For Vermont patients with commercial insurance, the Novartis Leqvio Connect co-pay assistance program can reduce out-of-pocket costs to $0 per injection for eligible patients, subject to program terms and income thresholds.

Vermont Medicaid (Green Mountain Care) covers inclisiran with prior authorization for beneficiaries diagnosed with HeFH or clinical ASCVD who meet LDL-C thresholds and step-therapy requirements [11]. Vermont's Catamount and Dr. Dynasaur programs follow the same PA criteria.

For uninsured or underinsured Vermont residents, the Novartis Patient Assistance Program (PAP) provides inclisiran at no cost for patients below 400 percent of the federal poverty level. Applications are submitted through Novartis's patient support line or via the prescriber's office. The NLA has published guidance on navigating manufacturer assistance programs for PCSK9-pathway agents that Vermont clinicians may find useful [15].

Medicare Part B covers inclisiran when administered in a physician's office or outpatient hospital setting because it is a provider-administered drug under the buy-and-bill model. Medicare Part D does not cover Leqvio. Vermont Medicare beneficiaries should confirm with their cardiologist's billing department whether the office participates in buy-and-bill for Part B drugs.

Transferring an Existing Leqvio Prescription to Vermont

Patients relocating to Vermont who are already established on inclisiran can transfer their care without restarting the prior authorization process in most cases. The key steps are:

1. Obtain a copy of your most recent fasting lipid panel and injection history from your prior provider.
2. Schedule a transfer-of-care visit with a Vermont-licensed prescriber (telehealth is acceptable).
3. Have the new prescriber submit a new PA to your Vermont insurer. Most Vermont payers accept a continuation PA with prior treatment history in lieu of a new step-therapy trial.
4. Enroll in the Leqvio Connect program under your new prescriber's NPI so the drug ships to the correct Vermont clinical site.

If your prior PA was issued by a BCBS plan in another state and you enroll in BCBS of Vermont, the new plan may honor the prior authorization for the remainder of the approval period (typically 12 months) under continuity-of-care provisions. Confirm this directly with BCBS of Vermont's specialty pharmacy team before your next scheduled injection.

Administration: What Happens at Each Vermont Injection Visit

Inclisiran is given as a single 284 mg subcutaneous injection into the abdomen, upper arm, or thigh. The injection is performed by a clinician or trained clinical staff member. The patient does not self-administer.

Each visit at a Vermont clinic or infusion center takes 15 to 30 minutes. The first 15 minutes following injection are recommended for observation, though serious hypersensitivity reactions are rare. Injection-site reactions (redness, pain, swelling) occurred in 2.6 percent of ORION-10 and ORION-11 participants and resolved without treatment in all cases [4].

Patients should bring their current medication list to each visit so the clinician can verify no new drug-drug interactions have emerged. Inclisiran has no significant cytochrome P450 interactions, but statins or other lipid-lowering agents added since the last visit should be documented [1]. A fasting lipid panel drawn before each injection visit confirms ongoing LDL-C suppression and satisfies payer requirements for continued authorization.